Literature DB >> 5114704

Studies of patients with osteogenesis imperfecta.

J A Albright, J A Grunt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5114704

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN： 0021-9355            Impact factor:   5.284


× No keyword cloud information.
  4 in total

1.  RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta.

Authors:  Renee Bargman; Alice Huang; Adele L Boskey; Cathleen Raggio; Nancy Pleshko
Journal:  Connect Tissue Res       Date:  2010-04       Impact factor: 3.417

2.  Eleven years of experience with bisphosphonate plus alfacalcidol treatment in a man with osteogenesis imperfecta type I.

Authors:  Jun Iwamoto; Yoshihiro Sato; Mitsuyoshi Uzawa; Hideo Matsumoto
Journal:  Ther Clin Risk Manag       Date:  2012-12-28       Impact factor: 2.423

3.  The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta.

Authors:  Ingmar Ipach; Torsten Kluba; Petra Wolf; Bertram Pontz; Falk Mittag
Journal:  Orthop Rev (Pavia)       Date:  2012-09-04

Review 4.  Syndromes with congenital brittle bones.

Authors:  Horacio Plotkin
Journal:  BMC Pediatr       Date:  2004-08-31       Impact factor: 2.125
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.